Related Experiment Video
Updated: Jun 12, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Diabetes: making sense of the rosiglitazone controversy
Michael E Farkouh1, Valentin Fuster
1Clinical Trials Unit, Mount Sinai Cardiovascular Institute, One Gustave L. Levy Place, Box 1074, New York, NY 10029, USA.
Abstract:
Whether thiazolidinediones should be used to treat patients with type 2 diabetes mellitus is controversial, as studies on the cardiovascular effects of these drugs have produced conflicting results. A trial in which rosiglitazone and glipizide were compared supports earlier findings that rosiglitazone does not have an adverse effect on the progression of coronary atherosclerosis.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetes Mellitus: Type 2 and Gestational
Dipeptidyl Peptidase 4 Inhibitors
Diabetes: Symptoms, Diagnosis, and Complications
